Format

Send to

Choose Destination
Pediatr Blood Cancer. 2018 Sep;65(9):e27265. doi: 10.1002/pbc.27265. Epub 2018 May 24.

Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.

Author information

1
Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.
2
Children's Center for Cancer and Blood Diseases and Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
3
Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington.
4
Department of Pediatrics, University of Washington, Seattle, Washington.

Abstract

A pediatric patient diagnosed initially with B-lymphoblastic leukemia (B-ALL) relapsed with lineage switch to acute myeloid leukemia (AML) after chimeric antigen receptor T-cell (CAR-T) therapy and hematopoietic stem cell transplant. A TCF3-ZNF384 fusion was identified at diagnosis, persisted through B-ALL relapse, and was also present in the AML relapse cell population. ZNF384-rearrangements define a molecular subtype of B-ALL characterized by a pro-B-cell immunophenotype; furthermore, ZNF384-rearrangements are prevalent in mixed-phenotype acute leukemias. Lineage switch following CAR-T therapy has been described in patients with KMT2A (mixed lineage leukemia) rearrangements, but not previously in any patient with ZNF384 fusion.

KEYWORDS:

AML; B-ALL; CAR-T; leukemia

PMID:
29797659
DOI:
10.1002/pbc.27265

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center